98%
921
2 minutes
20
Objectives: Under the auspices of the Asia-Pacific League of Associations for Rheumatology (APLAR), we aimed to develop broad, evidence- and consensus-based guidelines to aid health professionals managing patients with psoriatic arthritis (PsA) in the region.
Methods: A working group of 35 members comprising rheumatologists, dermatologists, and patient research partners from 18 APLAR countries was convened. The working group conducted systematic literature reviews to derive the quality of evidence via GRADE methods in supporting the efficacy and safety of classes of therapeutic agents for the management of active PsA, its comorbidities, and screening for specific infection concerns in the region. Recommendation statements on the principles of management and the best use of therapeutic drugs were developed. Consensus within the working group was achieved. An external voting panel, five from each of the 18 APLAR countries, was convened to confirm further agreement on the recommendation statements.
Results: The main literature review included 178 articles from clinical trials for PsA. Additional articles on the evidence for managing comorbidities, uveitis, inflammatory bowel disease, and screening for chronic hepatitis B and latent tuberculosis were reviewed. The working group discussed and reached consensus on eight management principles and 16 recommendation statements for managing PsA. Endorsement from an external voting panel (n = 90, response rate 80%) was achieved.
Conclusion: These first recommendations for the management of PsA patients in the APLAR regions were developed based on the best available evidence and region-specific considerations through discussion among rheumatologists, dermatologists, and patients, with strong agreement from an external expert panel.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/1756-185x.70372 | DOI Listing |
Pathogens
April 2025
Department of Health Sciences, University of Florence, 50134 Florence, Italy.
Italy was one of the first countries to implement a hepatitis B (HBV) immunization strategy in 1991; since its introduction, the epidemiology of this disease has significantly changed. The aim of this retrospective study was to assess the seroprevalence of three HBV markers (anti-HBs, anti-HBc, and HBsAg) and describe the acquired immunity in a representative sample of the adult general population in the province of Florence (Italy) between April 2018 and December 2019. We conducted an enzyme-linked immunosorbent assay on 430 serum samples collected from the adult general population to quantify anti-HBs titers and assess the presence of anti-HBc and HBsAg.
View Article and Find Full Text PDFVaccines (Basel)
September 2024
Department of Health Sciences, University of Florence, 50134 Florence, Italy.
Haematologica
August 2024
Antonino Trizzino, Simona Gobbi, Fraia Melchionda, Marco Zecca, Elena Mastrodicasa, Massimo Provenzi, Monica Cellini, Daniela Onofrillo, Marco Rabusin, Bernd Raffeiner, Rosamaria Mura, Vito Miraglia, Alessandra Tozzo.
Primary hemophagocytic lymphohistiocytosis (pHLH) is a severe, life-threatening hyperinflammatory syndrome caused by defects in genes of the granule-dependent cytotoxic pathway. Here we investigated the clinical presentation and outcome in a large cohort of 143 patients with pHLH diagnosed in the last 15 years and enrolled in the Italian registry. The median age at diagnosis was 12 months (interquartile range, 2-81), and 92 patients (64%) fulfilled the HLH-2004 criteria.
View Article and Find Full Text PDFMicrobiol Resour Announc
January 2024
Local Public Health Institutes, Japan.
Diving Hyperb Med
December 2023
Prepared by the Working Group «SAFETY» of the COST Action B14 «HYPERBARIC OXYGEN THERAPY» May 2004 - Update 2022.